ANI Pharmaceuticals Reports Record Second Quarter Results and Increases Full-year 2016 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Guggenheim Raises Price Target on ANI Pharma (ANIP) Following 2Q Earnings Report
August 4, 2016 3:49 PM EDTGuggenheim reiterated a Buy rating on ANI Pharmaceuticals (NASDAQ: ANIP), and raised the price target to $80.00 (from $65.00), following the company's 2Q earnings report. ANIP reported adjusted diluted EPS of $1.11, $0.31 higher than consensus estimates. ANIP raised its '16 EPS guidance range from $3.54-$3.91 to... More
ANI Pharma (ANIP) Tops Q2 EPS by 34c; Boosts FY16 Outlook
August 4, 2016 8:43 AM EDTANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $1.11, $0.34 better than the analyst estimate of $0.77. Revenue for the quarter came in at $31.34 million versus the consensus estimate of $27.63 million.
GUIDANCE:
ANI Pharma sees FY2016 EPS of $4.00-$4.25, versus the consensus... More
